Clinical applications of simultaneous PET/MR imaging using (R)-[11C]-verapamil with cyclosporin A: preliminary results on a surrogate marker of drug-resistant …

JW Shin, K Chu, SA Shin, KH Jung… - American Journal …, 2016 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: The development of resistance to antiepileptic drugs is
explained well by the transporter hypothesis, which suggests that drug resistance is caused …

Imaging P-glycoprotein function in rats using [11C]-N-desmethyl-loperamide

MD Farwell, DJ Chong, Y Iida, SA Bae… - Annals of nuclear …, 2013 - Springer
Objective One mechanism that may be responsible for drug resistance in epilepsy is the
upregulation of P-glycoprotein (P-gp), a drug efflux pump, at the epileptogenic focus. In this …

[HTML][HTML] A novel PET imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier

JP Bankstahl, M Bankstahl, C Kuntner… - The Journal of …, 2011 - ncbi.nlm.nih.gov
About one third of epilepsy patients are pharmacoresistant. Overexpression of P-
glycoprotein and other multidrug transporters at the blood-brain barrier is thought to play an …

P‐glycoprotein imaging in temporal lobe epilepsy: In vivo PET experiments with the Pgp substrate [11C]‐verapamil

M Feldmann, M Koepp - Epilepsia, 2012 - Wiley Online Library
Overexpression of the multidrug efflux transporter P‐glycoprotein (Pgp) at the blood–brain
barrier (BBB) is thought to be involved in pharmacoresistance in epilepsy by extruding …

Pharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein Substrate R‐[11C]verapamil

O Langer, M Bauer, A Hammers, R Karch… - …, 2007 - Wiley Online Library
Purpose and Methods: Regional overexpression of the multidrug transporter P‐glycoprotein
(P‐gp) in epileptic brain tissue may lower target site concentrations of antiepileptic drugs …

A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood–brain barrier

JP Bankstahl, M Bankstahl, C Kuntner… - Journal of …, 2011 - Soc Neuroscience
Approximately one-third of epilepsy patients are pharmacoresistant. Overexpression of P-
glycoprotein and other multidrug transporters at the blood–brain barrier is thought to play an …

P‐glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)‐[11C]verapamil PET

M Ilyas‐Feldmann, MC Asselin, S Wang… - …, 2020 - Wiley Online Library
Objective Overexpression of the drug transporter P‐glycoprotein (P‐gp) is thought to be
involved in drug‐resistance in epilepsy by extrusion of antiepileptic drugs (AEDs). We used …

An evaluation of the diagnostic equivalence of 18F-FDG-PET between hybrid PET/MRI and PET/CT in drug-resistant epilepsy: A pilot study

SE Poirier, BYM Kwan, MT Jurkiewicz, L Samargandy… - Epilepsy Research, 2021 - Elsevier
Abstract Objective Hybrid PET/MRI may improve detection of seizure-onset zone (SOZ) in
drug-resistant epilepsy (DRE), however, concerns over PET bias from MRI-based …

Imaging of P‐glycoprotein–mediated pharmacoresistance in the hippocampus: Proof‐of‐concept in a chronic rat model of temporal lobe epilepsy

H Bartmann, C Fuest, C La Fougere, G Xiong, T Just… - …, 2010 - Wiley Online Library
Purpose: Based on experimental findings, overexpression of P‐glycoprotein at the blood–
brain barrier has been suggested to be a contributor to pharmacoresistance of the epileptic …

Imaging of P glycoprotein Function in vivo with PET

NH Hendrikse, W Vaalburg - Mechanisms of Drug Resistance …, 2002 - Wiley Online Library
P glycoprotein (Pgp) is expressed on cell membranes of various organs in the body, such as
the capillary endothelial cells of the brain. Furthermore, Pgp can also be expressed on the …